References

1. Rybelsus^® Summary of Product Characteristics (SmPC), EU SmPC - PI (March 2024)
2. American Diabetes Association. Diabetes A to Z: What You Need to Know About Diabetes—Simply Put. 7th ed. Alexandria, VA: American Diabetes Association; 2016.
3. ADA, American Diabetes Association Standards of Care in Diabetes - 2024: Diabetes Care, December 2023, Vol.47, Supplement 1.
4. Wharton, S., et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine, (2021);134(1):14–19. https://doi.org/10.1080/00325481.2021.2002616.
5. Gorgojo-Martínez, J.J.; et al. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J. Clin. Med. 2023;12:145. https://doi.org/10.3390/jcm12010145.
6. Patient Information Leaflet (PIL) revision date March/2024